相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。How to better stratify the risk of differentiated thyroid carcinomas: the key role of radioactive iodine therapy, age, and gender
Arnoldo Piccardo et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
Benedikt Feuerecker et al.
EUROPEAN UROLOGY (2021)
Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will α Beat β?
Nattakorn Dhiantravan et al.
EUROPEAN UROLOGY (2021)
Pharmacogenomics in Radionuclide Therapy: Impact on Response to Theranostics
Andrew M. Scott et al.
JOURNAL OF NUCLEAR MEDICINE (2021)
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman et al.
LANCET (2021)
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET
Murali Kesavan et al.
ENDOCRINE-RELATED CANCER (2021)
PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology
Valentin Duclos et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
Murali Kesavan et al.
DIAGNOSTICS (2021)
Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy
Mike Sathekge et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia
Laura Palomo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States
Daniel J. George et al.
Clinical Genitourinary Cancer (2020)
Theranostic approaches in nuclear medicine: current status and future prospects
Luca Filippi et al.
EXPERT REVIEW OF MEDICAL DEVICES (2020)
The evolutionary dynamics and fitness landscape of clonal hematopoiesis
Caroline J. Watson et al.
SCIENCE (2020)
Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis
I. Vardarli et al.
BMC CANCER (2020)
Genetic Pathway in the Pathogenesis of Therapy-Related Myeloid Neoplasms: A Literature Review
Tegenaw Tiruneh et al.
ONCOLOGY AND THERAPY (2020)
The Future of Nuclear Medicine as an Independent Specialty
Johannes Czernin et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Predictive Factors of Recurrence in Patients with Differentiated Thyroid Carcinoma: A Retrospective Analysis on 579 Patients
Fabio Medas et al.
CANCERS (2019)
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
Matthias M. Heck et al.
EUROPEAN UROLOGY (2019)
Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Hendrik Bergsma et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial
Christopher C. Parker et al.
EUROPEAN UROLOGY (2018)
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016
Mazyar Shadman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer
Remco J. Molenaar et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Power of Absolute Values to Avoid Data Misinterpretations: The Case of Radioiodine-Induced Leukemia and Myelodysplasia
Arnoldo Piccardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Inconclusive Analysis of the Connection Between Secondary Hematologic Malignancies and Radioiodine Treatment
Michael C. Kreissl et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Risk of Hematologic Malignancies After Radioactive Iodine Treatment of Thyroid Cancer: An Unjustified Warning
Elif Hindie et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Questionable Relevance of Leukemia Risk After Radioiodine Ablation of Thyroid Cancer
Ronald Fisher
JOURNAL OF CLINICAL ONCOLOGY (2018)
Radioiodine Treatment of Well-Differentiated Thyroid Cancer: Balancing Risks and Benefits
Bennett S. Greenspan
JOURNAL OF CLINICAL ONCOLOGY (2018)
Well-Founded Recommendations for Radioactive Iodine Treatment of Differentiated Thyroid Cancer Require Balanced Study of Benefits and Harms
Mark Tulchinsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Selective Focus on Rare Hematologic Malignancies Misleads Risk-Benefit Assessment of Radioiodine Therapy of Thyroid Cancer
Mohan Doss
JOURNAL OF CLINICAL ONCOLOGY (2018)
Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Lessons from Confronting Controversial Literature on Risks for Secondary Malignancy
Mark Tulchinsky et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617:Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
Michael S. Hofman et al.
LANCET ONCOLOGY (2018)
Predicting progression to AML
Rob S. Sellar et al.
NATURE MEDICINE (2018)
Somatic mutations precede myeloid leukemia years before diagnosis
Pinkal Desai et al.
NATURE MEDICINE (2018)
Consolidation and maintenance in follicular lymphoma: radioimmunotherapy revisited?
Leo I. Gordon
LANCET HAEMATOLOGY (2018)
An introduction to the clinical practice of theranostics in oncology
J. Harvey Turner
BRITISH JOURNAL OF RADIOLOGY (2018)
Prediction of acute myeloid leukaemia risk in healthy individuals
Sagi Abelson et al.
NATURE (2018)
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
F. Morschhauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis
Jen-Der Lin et al.
NUCLEAR MEDICINE COMMUNICATIONS (2018)
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
Kambiz Rahbar et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
Rodney J. Hicks et al.
NEUROENDOCRINOLOGY (2017)
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
R. Marcus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Radiogenomics: Identification of Genomic Predictors for Radiation Toxicity
Barry S. Rosenstein
SEMINARS IN RADIATION ONCOLOGY (2017)
Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride
Hojjat Ahmadzadehfar et al.
ONCOTARGET (2017)
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Adam S. Sperling et al.
NATURE REVIEWS CANCER (2017)
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma
Narendranath Epperla et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Clinical significance of somatic mutation in unexplained blood cytopenia
Luca Malcovati et al.
BLOOD (2017)
Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination Lu-177-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy
Phillip G. Claringbold et al.
NEUROENDOCRINOLOGY (2016)
Implementing genomics and pharmacogenomics in the clinic: The National Human Genome Research Institute's genomic medicine portfolio
Teri A. Manolio
ATHEROSCLEROSIS (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience
Murali Kesavan et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2016)
'CHIP'ping away at clonal hematopoiesis
D. C. Link et al.
LEUKEMIA (2016)
Coming of age: ten years of next-generation sequencing technologies
Sara Goodwin et al.
NATURE REVIEWS GENETICS (2016)
Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression
Catherine A. Cargo et al.
BLOOD (2015)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study
Phillip G. Claringbold et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2015)
Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma
Jonathan Reiss et al.
LEUKEMIA & LYMPHOMA (2015)
Incidence and Burden of the Myelodysplastic Syndromes
Christopher R. Cogle
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Phase II study of first-line 131I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic 18F-fluorodeoxyglucose positron emission tomography
Andrew D. McQuillan et al.
LEUKEMIA & LYMPHOMA (2015)
Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation
Rafael Bejar et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver Sartor et al.
LANCET ONCOLOGY (2014)
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Mingchao Xie et al.
NATURE MEDICINE (2014)
Hematological Toxicity of Combined Lu-177-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up
Murali Kesavan et al.
NEUROENDOCRINOLOGY (2014)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity
Gillian C. Barnett et al.
RADIOTHERAPY AND ONCOLOGY (2014)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
A 2-Stage Genome-Wide Association Study to Identify Single Nucleotide Polymorphisms Associated With Development of Erectile Dysfunction Following Radiation Therapy for Prostate Cancer
Sarah L. Kerns et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Long-Term Outcomes Following Low-Dose Radioiodide Ablation for Differentiated Thyroid Cancer
Liam Welsh et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Bringing genome-wide association findings into clinical use
Teri A. Manolio
NATURE REVIEWS GENETICS (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Mutations affecting mRNAsplicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes
Frederik Damm et al.
BLOOD (2012)
A replicated association between polymorphisms near TNFα and risk for adverse reactions to radiotherapy
C. J. Talbot et al.
BRITISH JOURNAL OF CANCER (2012)
Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
Phillip G. Claringbold et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2012)
STANDARDIZED TOTAL AVERAGE TOXICITY SCORE: A SCALE- AND GRADE-INDEPENDENT MEASURE OF LATE RADIOTHERAPY TOXICITY TO FACILITATE POOLING OF DATA FROM DIFFERENT STUDIES
Gillian C. Barnett et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
Timothy A. Graubert et al.
NATURE GENETICS (2012)
Rare and common variants: twenty arguments
Greg Gibson
NATURE REVIEWS GENETICS (2012)
Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
Michael F. Leahy et al.
BLOOD (2011)
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida et al.
NATURE (2011)
Guidelines for radioiodine therapy of differentiated thyroid cancer
M. Luster et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities
J Pedersen-Bjergaard et al.
LEUKEMIA (2002)
分享论文
